Vamikibart (Roche, anti-IL-6) has shown that anti-IL-6 monotherapy can provide visual and anatomical improvement in patients with inflammatory macular edema 42 Sharma, et al. A Novel Intravitreal Anti-IL-6 Monoclonal Antibody for Uveitic Macular Edema (UME): Preliminary Results From the Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 28 – August 1, 2023 A clear dose response is seen with IL-6 monotherapy in patients with inflammatory macular edema DOVETAIL Change from Baseline in BCVA DOVETAIL Change from Baseline in OCT CST